NASDAQ · Biotechnology

Oncolytics Biotech Inc. (ONCY) Stock

$0.81 -0.78% NASDAQ: ONCY Healthcare

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.

Valuation

MetricValue
Price$0.81
Market Cap$80.88M
P/E Ratio-3.40
P/B Ratio-25.06
P/S Ratio0.00
EPS (TTM)$-0.41
52-Week High$1.51
52-Week Low$0.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE780.00%
ROA-435.28%
ROCE-1950.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.10
Current Ratio1.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-21.0M$-25.0M$-35.0M$-39.0M
Net Profit$-21.0M$-19.0M$-21.0M$-32.0M$-39.0M
EPS$-0.49$-0.44$-0.41$-0.41$-0.41
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$46.0M$37.0M$39.0M$20.0M$10.0M
Total Liabilities$10.0M$11.0M$11.0M$14.0M$16.0M
Cash$41.0M$12.0M$35.0M$16.0M$7.0M
Borrowings$1.0M$0$0$1.0M$1.0M

Latest News

Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) InvestorsHub · Jul 13, 2026 Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial GlobeNewswire · Jul 13, 2026 Sector Update: Healthcare Stocks Ease Late Afternoon MT Newswires · Jun 16, 2026 Sector Update: Healthcare Stocks Advance in Afternoon Trading MT Newswires · Jun 16, 2026 Sector Update: Healthcare MT Newswires · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-23.0M$-28.0M$-27.0M$-28.0M
Investing Cash Flow$-1.0M$-20.0M$20.0M$0$0
Financing Cash Flow$0$0$1.0M$0$0
Net Cash Flow$10.0M$-30.0M$23.0M$-19.0M$-8.0M
Free Cash Flow$-23.0M$-23.0M$-28.0M$-27.0M$-28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.41
EV / EBITDA-3.00
FCF Yield-34.62%
Quick Ratio1.13
Interest Coverage0.00
Return 1Y-19.12%
Return 3Y-69.02%
Return 5Y-61.44%

Ownership

Insiders Held2.19%
Institutions Held3.31%
Institutions Float Held3.39%
Institutional HolderSharesReport Date
Marshall Wace LLP859,8312026-03-31
Renaissance Technologies, LLC715,8382026-03-31
Sandbox Financial Partners, LLC400,0002026-03-31
Seeds Investor LLC 258,3062026-03-31
Tocqueville Asset Management L.p.149,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATOS $2.36 -2.48% -1.23 $23.54M 0.00%
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc. is led by CEO Jared Kelly, employs 28 people, headquartered in CA, publicly traded since 2001.

Oncolytics Biotech Inc. (ONCY) stock trades at $0.81 with a market capitalization of $80.88M. The stock is valued at a price-to-earnings (P/E) ratio of -3.40, price-to-book of -25.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.77 and $1.51, and currently trades 46.4% below its 52-week high.

On profitability, Oncolytics Biotech Inc. generates a return on equity (ROE) of 780.00% — well above the market average, a sign of a high-quality business, return on capital employed of -1950.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.oncolyticsbiotech.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides